Qualifyze

Qualifyze provides supplier risk management and audit software for healthcare and life sciences companies. Its offering has two main parts: an Audit Management Platform, used to plan, execute and track internal and external supplier audits, manage CAPAs with automated tracking and alerts, and access a library of ready-to-use audit reports; and a Quality Insights Platform, which combines audit outcomes, operational quality metrics, inherent manufacturing risk and regulatory supervision signals (such as inspections and warning letters from authorities including the FDA and EMA) into a continuous, AI-supported view of supplier risk.

The company was founded by Dr. David Schneider, a former McKinsey consultant, who started with the idea of a B2B marketplace for procuring pharmaceutical ingredients and supply chain services before pivoting to supplier quality and regulatory qualification. Qualifyze combines a network of quality assurance auditors — a mix of employees and contractors, supported by in-house training and vetting — with a database of suppliers and buyers used to assess compliance against fragmented industry standards including GxP, ESG, ISO and CAPA follow-ups.

The platform is aimed at quality assurance, audit management and procurement teams, giving them a shared view of supplier risk, supplier qualification decisions and audit status. The company states audit report access can reduce audit execution time by 65% and audit costs by 40%.

Founding story

Founder and CEO Dr. David Schneider, who holds a doctorate in strategy and management and previously worked as a McKinsey consultant, observed inefficiency and paper-based processes among pharmaceutical clients. His initial concept was a B2B marketplace for sourcing drug development ingredients and services, but the company pivoted after concluding that the harder problem was determining whether suppliers met quality and regulatory requirements rather than finding suppliers or negotiating price.

Business model

Qualifyze sells access to shared, ready-to-use audit reports and to on-demand audits carried out by its network of expert auditors, alongside SaaS platforms for audit management and supplier quality insights. Its model is anchored around people — auditors, some employed and some contracted — with technology used to manage information, run analytics and capture data on manufacturing processes. Platform access is offered without per-seat user limits.

Revenue derives from audits and audit report access for buyers and suppliers in the life sciences supply chain, plus platform-based audit management and quality insights products.

Traction

As of the September 2024 Series B, Qualifyze worked with a network of 250 auditors covering a database of roughly 3,000 suppliers serving 1,200 customers. Company materials cite more than 6,000 ready-to-use audit reports with 250+ new reports added monthly, over 1,000 life science customers, a claimed 65% reduction in audit execution time, 40% reduction in audit costs, and 95% accuracy of AI risk predictions. A published case study describes Recipharm increasing supplier audit capacity by 50%.

Latest developments

The company raised a $54 million Series B in September 2024 led by Insight Partners with participation from HV Capital, HarbourVest Partners, H14 and Cherry Ventures, earmarked for U.S. expansion and additional analytics and AI capabilities. It has also assembled a senior advisory group including former FDA Associate Commissioner for Inspections and Investigations Michael Rogers, former Biogen Chief Quality Officer Juan Torres, former Johnson & Johnson VP of Global MedTech Supply Chain Filip De Keersmaecker, and McKinsey Senior Partner Emeritus Steve Van Kuiken.